secwatch.observer — SEC 8-K summary
======================================

Issuer:     Royalty Pharma plc (RPRX)
CIK:        0001802768
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001193125-24-251698
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Royalty Pharma Q3 portfolio receipts up 15% to $735M; raises FY guidance to $2.75-2.8B
--------------------------------------------------------------------------------

- Royalty Receipts grew 15% to $732M; Portfolio Receipts $735M, driven by Trelegy, Evrysdi, cystic fibrosis franchise.
- Full-year 2024 Portfolio Receipts guidance raised to $2.75B-$2.8B (from $2.7B-$2.775B); Royalty Receipts growth 11-13%.
- Capital Deployment of ~$1.2B in Q3; acquired synthetic royalties on Niktimvo ($350M) and Yorvipath ($150M).
- Net cash from operations $704M; repurchased ~3M shares for $95M during Q3; cash and equivalents $950M.
- FDA approvals for Cobenfy (schizophrenia), Tremfya (ulcerative colitis), Voranigo (glioma) benefit royalty portfolio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802768/000119312524251698/0001193125-24-251698-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802768/000119312524251698/d904706d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-251698

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer